Everest Medicines Limited (HKG: 1952) announced that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) to transfer the manufacturing of VELSIPITY (etrasimod arginine tablets) from overseas to China — and has granted the filing Priority Review. The supplement concerns the company’s next‑generation, highly selective S1P receptor modulator, approved in China in February 2026 for moderately to severely active ulcerative colitis (UC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Type | New Drug Application (NDA) – manufacturing site transfer (overseas → China) |
| Product | VELSIPITY (etrasimod arginine tablets) |
| Review Designation | Priority Review granted |
| Indication | Adults with moderately to severely active ulcerative colitis (UC) with inadequate response, loss of response, or intolerance to conventional or biologic therapies |
| Original China Approval | February 2026 |
| Acceptance Date | 17 Sep 2026 |
| Review Timeline | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Etrasimod (as etrasimod arginine tablets), marketed as VELSIPITY.
- Class: Next‑generation, highly selective S1P (sphingosine‑1‑phosphate) receptor modulator — sequestering lymphocytes in lymphoid tissue to reduce gut inflammation.
- Regimen: Oral, once‑daily administration — distinguishing it from infusion‑ or injection‑based biologics in the UC armamentarium.
- Clinical Profile: Positioned as offering rapid onset, potent and deep mucosal healing, and a favorable safety profile, with the company asserting best‑in‑disease potential. Specific trial datasets were not detailed in the announcement.
- Origin: Developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022.
- Licensing: Etrasimod was exclusively licensed by Everest Medicines in 2017 for development, manufacturing, and commercialization in Greater China and South Korea.
Regional Regulatory Footprint
| Market | Status |
|---|---|
| Mainland China | Approved (Feb 2026) |
| Hong Kong | Approved |
| Macao | Approved |
| Singapore | Approved |
| South Korea | Approved |
| Taiwan, China | Approval expected 2H 2026 |
Within Everest’s licensed territories, VELSIPITY has received regulatory approvals in Mainland China, Hong Kong, Macao, Singapore, and South Korea, and is expected to gain approval in Taiwan, China in the second half of 2026.
Market Impact & Outlook
- Localization Strategy: Transferring manufacturing from overseas to China is a strategic move that can strengthen supply security, reduce logistics and tariff exposure, and support national reimbursement and procurement participation — increasingly important for innovative drugs scaled across the Chinese market.
- Priority Review Signal: The NMPA’s Priority Review designation accelerates the supplemental review, shortening the path to China‑made commercial supply; specific review timelines were not disclosed.
- UC Competitive Landscape: The moderately to severely active UC market in China features JAK inhibitors, S1P modulators, and multiple biologics; an oral once‑daily option with rapid onset and mucosal‑healing claims positions VELSIPITY competitively for both biologic‑naïve and biologic‑experienced patients.
- Regional Expansion: The anticipated Taiwan, China approval in 2H 2026 would complete VELSIPITY’s rollout across Everest’s licensed Greater China and South Korea footprint.
- Next Catalysts: NMPA review outcome of the manufacturing‑transfer NDA; the expected Taiwan, China approval; commercial uptake data — timing details beyond 2H 2026 not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the NMPA review of the manufacturing‑transfer NDA, the expected approval of VELSIPITY in Taiwan, China in the second half of 2026, and the commercial potential of etrasimod. Acceptance and Priority Review designation do not guarantee approval. Actual results may differ materially due to risks including regulatory review outcomes, manufacturing technology transfer execution, reimbursement dynamics, and competitive pressures.-Fineline Info & Tech
